Computed tomography imaging for novel therapies of chronic obstructive pulmonary disease

• Verfasst von: Kauczor, Hans-Ulrich [VerfasserIn]
• Verfasst von: Wielpütz, Mark Oliver [VerfasserIn]
• Verfasst von: Jobst, Bertram [VerfasserIn]
• Verfasst von: Weinheimer, Oliver [VerfasserIn]
• Verfasst von: Gompelmann, Daniela [VerfasserIn]
• Verfasst von: Herth, Felix [VerfasserIn]
• Verfasst von: Heußel, Claus Peter [VerfasserIn]
• Titel: Computed tomography imaging for novel therapies of chronic obstructive pulmonary disease
• Verf.angabe: Hans-Ulrich Kauczor, Mark O. Wielpütz, Bertram J. Jobst, Oliver Weinheimer, Daniela Gompelmann, Felix J. F. Herth, Claus P. Heussel
• E-Jahr: 2019
• Jahr: 2019/05/01
• Umfang: 10 S.
• Teil: volume:34
• Teil: year:2019
• Teil: number:3
• Teil: pages:202-213
• Teil: extent:10
• Fussnoten: Gesehen am 11.07.2019
• Titel Quelle: Enthalten in: Journal of thoracic imaging
• Ort Quelle: Philadelphia, Pa. : Lippincott Williams & Wilkins, 1985
• Jahr Quelle: 2019
• Band/Heft Quelle: 34(2019), 3, Seite 202-213
• ISSN Quelle: 1536-0237
• DOI: doi:10.1097/RTI.0000000000000378
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1669016307

Abstract

Novel therapeutic options in chronic obstructive pulmonary disease (COPD) require delicate patient selection and thus demand for expert radiologists visually and quantitatively evaluating high-resolution computed tomography (CT) with additional functional acquisitions such as paired inspiratory-expiratory scans or dynamic airway CT. The differentiation between emphysema-dominant and airway-dominant COPD phenotypes by imaging has immediate clinical value for patient management. Assessment of emphysema severity, distribution patterns, and fissure integrity are essential for stratifying patients for different surgical and endoscopic lung volume reduction procedures. This is supported by quantitative software-based postprocessing of CT data sets, which delivers objective emphysema and airway remodelling metrics. However, the significant impact of scanning and reconstruction parameters, as well as intersoftware variability still hamper comparability between sites and studies. In earlier stage COPD imaging, it is less clear as to what extent quantitative CT might impact decision making and therapy follow-up, as emphysema progression is too slow to realistically be useful as a mid-term outcome measure in an individual, and longitudinal data on airway remodelling are still very limited.